Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03288714 · ClinicalTrials.gov registry record · NA
Adaptive Design Study of NEST sTMS in Subjects With Major Depressive Disorder
A NA study, sponsored by Wave Neuroscience.
- Completed
- Registry status
- NA
- Development phase
- 121
- Enrollment target
NCT03288714: Completed NA study, sponsored by Wave Neuroscience.
NCT03288714 is a NA study that has completed, run by Wave Neuroscience. The registered enrollment target is 121 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03288714, a NA study, has completed, sponsored by Wave Neuroscience.
- COMPLETED
- Registry status
- NA
- Development phase
- 121 participants
- Enrollment target
Study Summary
This is a double-blind, sham controlled, multi-center study to confirm the safety and efficacy of synchronized transcranial magnetic stimulation (sTMS) for the treatment of patients currently experiencing an episode of depression who have failed to respond to at least one (1) antidepressant medication. Patients will be randomly assigned to either active or sham therapy and will undergo daily treatments for a period of time. Following completion of blinded treatments, patients may be eligible for a course of open label treatments.
Primary Outcome
Number of participants at the end of each treatment week who saw a reduction of at least 50% in baseline Hamilton Depression Rating Scale (HAMD-17) scores from baseline to week 6, compared between the active treatment and sham-controlled groups. The Hamilton Depression Rating Scale (HAMD-17) system asks 17 questions to rank subject on a scale ranges between 0-52, with higher numbers indicating more severe symptoms. 0-7 is generally accepted to be within the normal range (or in remission), while
Interventions
- DEVICE Sham Stimulation
- DEVICE Synchronized Transcranial Magnetic Stimulation (sTMS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2017-11-27 |
| Est. Completion | 2019-06-01 |
| Phase | NA |
What the finished NCT03288714 record still lists
NCT03288714 is an interventional study that assigns participants to a tested intervention. The registered 121 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 2 interventions - of which Sham Stimulation is the first listed.
NCT03288714 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03288714 about?
NCT03288714 is a clinical study titled "Adaptive Design Study of NEST sTMS in Subjects With Major Depressive Disorder". This is a double-blind, sham controlled, multi-center study to confirm the safety and efficacy of synchronized transcranial magnetic stimulation (sTMS) for the treatment of patients currently experiencing an episode of depression who have failed to respond to at least one (1) antidepressant medicati...
What is the current status of trial NCT03288714?
This trial is currently completed. It is a NA study. The enrollment target is 121 participants. The study started on 2017-11-27. Estimated completion is 2019-06-01.
What interventions are being tested in trial NCT03288714?
The interventions under investigation include: Sham Stimulation (DEVICE), Synchronized Transcranial Magnetic Stimulation (sTMS) (DEVICE).
Who is sponsoring clinical trial NCT03288714?
This trial is sponsored by Wave Neuroscience, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03288714's enrollment target sits among peer trials
121 762nd of 2000 higher than 1,239 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03476681 · 121 participants · Phase 1
Study of NEO-201 in Solid Tumors Expansion Cohorts
- NCT04655118 · 121 participants · Phase 2
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
- NCT04676802 · 121 participants · Phase 2
Pain Relief After Trapeziectomy: Ibuprofen & Acetaminophen Versus Oxycodone
- NCT05169515 · 121 participants · Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI